| Revenue growth | FY26 Consolidated: 1.5% YoY; Innoxel: 174% YoY. |
|---|---|
| Margins | Consolidated EBITDA margin 4.6%; FY27 standalone target 10-15%. |
| Order book | ₹171Cr (Tenders ₹119Cr, Exports ₹33Cr, Intl ₹20Cr). |
| Demand visibility | Strong order book of ₹171Cr for standalone BPL. |
| Management confidence | High; labeled FY27 as 'commercial inflection' year. |
Growth
Consolidated revenue grew 1.5% YoY; Innoxel subsidiary revenue ramped 174% YoY to ₹72.4Cr.
Outlook
FY27 guidance targets 10-15% BPL growth and 35-45% Innoxel growth with EBITDA break-even expected in Q1.
Risks
Consolidated PAT remains negative; standalone BPL revenue declined 23% YoY due to an outlier Q1 base.
Earnings Call filed with BSE, BSE: 541096. Summary written with AI assistance from the document.
Bharat Parenterals Ltd: key numbers
- Share price
- ₹1,895.10
- Market cap
- ₹1,306 Cr
- Revenue (annual)
- ₹345.4 Cr
- Net profit (annual)
- ₹-8.19 Cr
- P/E (TTM)
- -84.8×Sector 50.4×
- Promoter holding
- 67.20%+0.03% QoQ
- FII holding
- 0.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bharat Parenterals Ltd
All →Bharat Parenterals Board Meeting Date
Bharat Parenterals intimated that its Board will meet on 29 September 2026 to consider a preferential equity issue. The agenda item is proposed, not yet approved, with no amount disclosed.
Bharat Parenterals Management Change
Bharat Parenterals Limited has re-appointed Mr. Hemang Jayendrabhai Shah as Executive Director for a 5-year term effective July 2, 2026.
Bharat Parenterals Annual General Meeting
Bharat Parenterals Limited held its 33rd Annual General Meeting on September 19, 2026. The proceedings covered the adoption of financial statements and various resolutions.
Bharat Parenterals Investor Presentation: Key Takeaways
Q1 FY27 consolidated revenue fell 19% YoY to ₹93.7 Cr due to standalone institutional order base effects. Gross margins expanded 1,000bps to 50.6%, though consolidated PAT remained negative at ₹(3.6) Cr.
- Call
- Guides 25% growth
Bharat Parenterals Q1 FY27 Results: Net Loss of ₹3.6 Cr, Loss Widens
Bharat Parenterals Ltd reported revenue from operations of ₹93.7 Cr (-19.2% YoY) and a net loss of ₹3.6 Cr for Q1 FY27.
- Key figure
- Net loss ₹3.6 Cr
Bharat Parenterals Earnings Call: Key Takeaways
Bharat Parenterals reported flat FY26 consolidated revenue of ₹345.4cr but a 6x EBITDA surge to ₹15.8cr. Transition year focused on regulatory clearances and scaling subsidiaries like Innoxel and Varenyam.